Evert B. Schimmelpennink Net Worth

The estimated Net Worth of Evert B. Schimmelpennink is at least $15.1 million dollars as of 11 September 2018. Evert Schimmelpennink owns over 10,000 units of Pfenex stock worth over $15,083,096 and over the last 7 years Evert sold PFNX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Evert Schimmelpennink PFNX stock SEC Form 4 insiders trading

Evert has made over 1 trades of the Pfenex stock since 2018, according to the Form 4 filled with the SEC. Most recently Evert bought 10,000 units of PFNX stock worth $50,400 on 11 September 2018.

The largest trade Evert's ever made was buying 10,000 units of Pfenex stock on 11 September 2018 worth over $50,400. On average, Evert trades about 1,250 units every 0 days since 2017. As of 11 September 2018 Evert still owns at least 26,658 units of Pfenex stock.

You can see the complete history of Evert Schimmelpennink stock trades at the bottom of the page.

What's Evert Schimmelpennink's mailing address?

Evert's mailing address filed with the SEC is C/O IBIO, INC., 8800 HSC PARKWAY, BRYAN, TX, 77807.

Insiders trading at Pfenex

Over the last 10 years, insiders at Pfenex have traded over $99,496,796 worth of Pfenex stock and bought 36,000 units worth $174,640 . The most active insiders traders include Chemical Co /De/ Dow, James C Gale et Healthcare Partners Accredi.... On average, Pfenex executives and independent directors trade stock every 46 days with the average trade being worth of $90,240,574. The most recent stock trade was executed by Asset Management Lpweiss An... on 29 September 2020, trading 100,000 units of PFNX stock currently worth $1,274,000.

What does Pfenex do?

Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Complete history of Evert Schimmelpennink stock trades at iBio Inc et Pfenex

Pfenex executives and stock owners

Pfenex executives and other stock owners filed with the SEC include:

• Shawn Scranton,
  Chief Operating Officer
• Susan A. Knudson,
  Chief Financial Officer
• Evert B. Schimmelpennink,
  See Remarks
• Patricia Lady,
  Chief Accounting Officer
• Jason Grenfell Gardner,
  Director
• Martin Brenner,
  Chief Scientific Officer
• Magda Marquet,
  Director
• Phillip M Schneider,
  Director
• Sigurdur O Olafsson,
  Director
• Hubert C Chen,
  Chief Medical Officer
• John Mack Taylor,
  Director
• Patrick K. Lucy,
  Chief Business Officer
• Robin Campbell,
  Director
• Lorianne Masuoka,
  Director
• Dennis M Fenton,
  Director
• William R Rohn,
  Director
• Henry W. Jr. Talbot,
  VP of Research & Operations
• Healthcare Partners Accredi...,
  10% owner
• Bertrand C. Liang,
  Chief Executive Officer
• Steven S. Sr. Sandoval,
  Chief Manufacturing Officer
• Paul A. Wagner,
  Chief Financial Officer
• Chemical Co /De/ Dow,
  10% owner
• Healthcare Partners Accredi...,
  
• James C Gale,
  Director
• Asset Management Lpweiss An...,
  
• Management, Llc Newtyn,
  10% owner